ArticleUrologic oncology2021
Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02680041 (The Impact of 18F Fluciclovine), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.Prostate cancer and prostatic diseases · 2023Review
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
- Oligometastatic Prostate Cancer: Current Status and Future Challenges.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- [Cancers · 2022Article
- Positivity Rate of [Molecular imaging and biology · 2022Article
- Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer.Cancer management and research · 2022Review
- Clinical utility ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionDespite improvements in overall survival, biochemical recurrence of prostate cancer, characterized by rising prostate-specific antigen (PSA) levels after curative intent primary therapy, remains common. With the advent of highly sensitive molecular imaging, men with limited metastatic disease burden, or oligometastatic prostate cancer, are increasingly being identified. The LOCATE trial (NCT02680041) assessed the impact of positron emission tomography (PET) with
methodsEligible men (≥18 years; prior curative intent treatment of prostate cancer; recurrence based on rising PSA; negative/equivocal conventional imaging) underwent
resultsOf 213 enrolled patients, 164 (77%) had undergone prostatectomy as their initial treatment; their median PSA was 0.57ng/ml. For the 49 patients with an intact prostate, the median PSA was 5.5ng/ml. The overall
conclusionEven at low PSA levels,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.